Safety of Thiopurine Use in Paediatric Gastrointestinal Disease

Erasmo Miele, Marc A. Benninga, Ilse Broekaert, Jernej Dolinsek, Emmanuel Mas, Rok Orel, Corina Pienar, Carmen Ribes-Koninckx, Rut A. Thomassen, Mike Thomson, Christos Tzivinikos, Nikhil Thapar

Research output: Contribution to JournalArticleAcademicpeer-review


Thiopurines, alone or in combination with other agents, have a pivotal role in the treatment of specific gastrointestinal and hepatological disorders. In inflammatory bowel disease and autoimmune hepatitis thiopurines have proven their value as steroid sparing agents for the maintenance of remission and may be considered for preventing postoperative Crohn disease recurrence where there is moderate risk of this occurring. Their use with infliximab therapy reduces antibody formation and increases biologic drug levels. The routine clinical use of thiopurines has, however, been questioned due to a number of potential adverse effects. The aim of this article is to provide information regarding the use, and in particular, safety of these agents in clinical practice in the light of such potentially severe, albeit rare, effects.
Original languageEnglish
Pages (from-to)156-162
Number of pages7
JournalJournal of Pediatric Gastroenterology and Nutrition
Issue number2
Publication statusPublished - 1 Aug 2020

Cite this